MREO Stock Forecast & Price Target

Mereo BioPharma Group is supported by a pipeline of late-stage rare-disease assets with clear external validation, especially alvelestat, which targets the lung manifestations of AATD that antisense liver-directed approaches do not address. The Sentynl option agreement meaningfully de-risks development by potentially funding Phase III, delivering $40M upfront for clinical development, up to $435M in milestones, and double-digit U.S. royalties while preserving ex-U.S. rights for Mereo. Setrusumab remains in regulatory discussions, and the additional monetization of ex-Europe vantictumab rights in August 2025 highlights a portfolio with multiple shots on goal and underappreciated optionality.

Mereo BioPharma Group is a development-stage biopharmaceutical company whose value depends heavily on late-stage assets, leaving it exposed to binary clinical readout risk, regulatory uncertainty, and the possibility that commercialization proves more difficult in increasingly price-sensitive markets. Its financial profile also looks fragile because it will require additional funds to advance its programs, and there is no assurance that financing, milestone receipts from Ultragenyx, or new partnering deals will materialize on favorable terms. Even with NPV-based valuation assumptions using a 25% discount rate and -2.5% terminal growth rate, the business remains highly dependent on setrusumab and alvelestat, making any setback in development or funding a meaningful threat to shareholder value.